Business Wire

TA Associates Announces Strategic Growth Investment in Elos Medtech

Share

TA Associates, a leading global growth private equity firm, today announced it has completed a majority growth investment in Elos Medtech AB (NASDAQ STOCKHOLM: ELOS B), a leading innovative full-service contract development and manufacturing organization (CDMO) in the global medical device market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210726005835/en/

Founded in 1923, Elos Medtech is headquartered in Gothenburg, Sweden with operations being conducted at facilities in Sweden, Denmark, China and the U.S. As a global solutions partner offering complete performance and vertical integration to leading medical device companies worldwide, Elos Medtech serves the dental, orthopaedic and life science markets. In long-term partnership with their customers, Elos Medtech provides sustainable and innovative products and supply solutions for the global medical device and life science market.

“We have followed Elos Medtech for several years and have been highly impressed by the company and its management team,” said Lovisa Lander, a Principal at TA. “Given its well-earned reputation for quality and reliability, we believe Elos Medtech is well-positioned to further grow market share as a partner of choice for leading medical technology and life science companies around the world. With our knowledge, network and financial resources, we believe that TA can support the investments that will be required to help the company continue its growth journey. We look forward to working with the Elos Medtech team to solidify its position as a global, high-quality development and manufacturing partner with a MedTech focus.”

“I am very pleased to welcome TA as the majority shareholder of Elos Medtech,” said Jan Wahlström, CEO of Elos Medtech. “Having completed more than 70 investments in healthcare businesses, including many in the medical device field, TA has the deep experience, network and global resources that we believe will prove highly beneficial at this stage of our growth. I thank all our shareholders as well as our skilled and motivated employees for their support of Elos Medtech and look forward to a close partnership with TA as we continue to further build a strong global group.”

“With a focus on innovation and precision, Elos Medtech has proven highly adept at meeting the varied demands and requirements of its target markets with turnkey solutions that add substantial value,” said Birker Bahnsen, a Managing Director at TA. “In line with the unanimous recommendation by the company’s board of directors, we believe that TA is well placed to support the investments required in the next phase of Elos Medtech’s journey. As long-term investors, we welcome the opportunity to help the company achieve its strategic goals and reach its full potential.”

Roschier served as legal counsel to TA.

Details of the Transaction

On June 11, 2021, TA (through a newly established company under name change to EM Intressenter AB) announced a public offer to the shareholders of Elos Medtech to tender all their shares in Elos Medtech to EM Intressenter for SEK 215 per share. On July 7, 2021, TA announced that the Offer would be completed and that the initial acceptance period, which ended on July 5, 2021, would be extended and open until July 14, 2021. The total amount of shares tendered in the Offer at the end of the extended acceptance period on July 14, 2021 amount in aggregate to approximately 79.5 per cent of the share capital and 65.0 per cent of the voting rights in Elos Medtech.

About Elos Medtech AB

Elos Medtech is a leading development and production partner for medical devices. Elos Medtech offers innovative comprehensive solutions, from concept to finished project, through its Complete Performance™ concept. Elos Medtech is active in the dental, orthopaedics, and life science market segments. For more information, please visit www.elosmedtech.com.

About TA Associates

TA is a leading global growth private equity firm. Focused on targeted sectors within five industries – technology, healthcare, financial services, consumer and business services – the firm invests in profitable, growing companies with opportunities for sustained growth, and has invested in more than 535 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in high quality growth companies. TA has raised $47.5 billion in capital since its founding in 1968 and is committing to new investments at the pace of over $3 billion per year. The firm’s more than 100 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. More information about TA can be found at www.ta.com.

Important Notices

No United States of America securities regulatory authority has either approved or disapproved of the contents of this news release. This news release does not constitute an offer to sell, or a solicitation to buy, any securities of Elos Medtech in the United States of America or any other jurisdiction in which such offer or solicitation would be unlawful.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Marcia O’Carroll
TA Associates
+ 1-617-574-6796
mocarroll@ta.com

Stephen Fishleigh
BackBay Communications
+44-203-475-7552
stephen.fishleigh@backbaycommunications.com

Philip Nunes
BackBay Communications
+ 1-617-391-0792
Phil.nunes@backbaycommunications.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches21.9.2021 15:00:00 EEST | Press release

Boehringer Ingelheim today announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology research to develop the next generation of precision medicines designed to revolutionize cancer treatments. The acquisition will allow Boehringer Ingelheim to access Abexxa’s expertise in targeting cancer-specific proteins that are located inside the cell, rather than those expressed on the cell membrane. This enlarges the pool of potential cancer antigen targets. In particular, Abexxa’s technology could lead to the development of cancer immunotherapies that are effective in a broader range of patients and cancer types. “The acquisition of Abexxa bolsters our commitment to tumor-antigen discovery and new ways of targeting intracellular antigens. Their cutting-edge know-how and technologies for antigen discovery and novel antibody generation strongly complement the current approaches we have been applying successfu

CreatorIQ Expands Its Leadership Position With Acquisition of #1 Influencer Marketing Analytics Platform Tribe Dynamics21.9.2021 15:00:00 EEST | Press release

Influencer marketing platform, CreatorIQ — the most trusted partner advancing the creator economy for brands like AB InBev, Disney, Sephora, and Unilever — today announced the acquisition of the #1 influencer marketing analytics platform, Tribe Dynamics. The deal brings together Tribe Dynamics’ advanced analytics and benchmarking solutions — the industry standard for beauty and fashion brands like Estee Lauder, Fashion Nova, and LVMH — with the ability to make those insights actionable through CreatorIQ’s Creator Intelligence Cloud. The combined company will extend CreatorIQ’s leadership position as the largest influencer marketing SaaS platform in terms of revenue, growth, data authority, and global expansion with over 450 customers, 250 employees, and $90 million in funding. The companies provide an end-to-end solution for marketers to find, activate, manage and measure their creator relationships. As influencer marketing continues to grow in size, scope, and maturity, brands need in

Trialbee and Castor Partner to Democratize Access and Simplify Enrollment to Clinical Trials Globally21.9.2021 14:58:00 EEST | Press release

Trialbee, the leading enrollment performance company, and Castor, a leading provider of decentralized and hybrid clinical trial solutions, today announced a strategic partnership to accelerate patient enrollment, optimize patient engagement, and reduce site burden for clinical trials globally. Castor and Trialbee’s logical integration allows sponsors to meet enrollment timelines with continuous access to all their study data. Together, the fast-growing companies will expedite patient recruitment and streamline clinical trials through advanced data science and streamlined workflows for patient enrollment, data collection, and engagement. The partnership will diversify patient participation and improve equitable health outcomes for global decentralized and hybrid clinical programs. “We are excited to partner with Trialbee to improve patient engagement, as well as optimize patient diversity and study inclusivity with real-time insights around patient demographics across all recruitment ch

Trialbee and Castor Partner to Democratize Access and Simplify Enrollment to Clinical Trials Globally21.9.2021 14:58:00 EEST | Press release

Trialbee, the leading enrollment performance company, and Castor, a leading provider of decentralized and hybrid clinical trial solutions, today announced a strategic partnership to accelerate patient enrollment, optimize patient engagement, and reduce site burden for clinical trials globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005005/en/ Castor and Trialbee’s logical integration allows sponsors to meet enrollment timelines with continuous access to all their study data. Together, the fast-growing companies will expedite patient recruitment and streamline clinical trials through advanced data science and streamlined workflows for patient enrollment, data collection, and engagement. The partnership will diversify patient participation and improve equitable health outcomes for global decentralized and hybrid clinical programs. “We are excited to partner with Trialbee to improve patient engagement, as well as

Theramex launches Bijuva® / Bijuve® (estradiol and progesterone), the first and only body-identical combined hormone therapy treatment for post-menopausal women*21.9.2021 14:45:00 EEST | Press release

PRESCRIBING INFORMATION IS AVAILABLE AT THE END OF THIS RELEASE FOR MEDICAL BUSINESS / HEALTHCARE INDUSTRY TRADE MEDIA ONLY Theramex has today launched Bijuva® / Bijuve® (1mg estradiol / 100mg progesterone) across Europe and the UK. Bijuva®, (known as Bijuve® in the UK), is the first, and only, body-identical hormone therapy treatment (HRT) for estrogen deficiency symptoms in post-menopausal women with intact uterus and at least 12 months since last menses, which combines estradiol and progesterone in a single daily oral capsule.1,2 Unlike synthetic hormone products, the estradiol and progesterone found in Bijuva® / Bijuve® are chemically and biologically identical to the hormones naturally circulating in the woman’s body.3 Real-world evidence, recognised by NICE and the British Menopause Society, suggests that use of body‑identical hormones is associated with lower risks compared to synthetic versions. 4,5 In particular, the evidence base demonstrates that body-identical hormones have

Hologic Releases Results of Inaugural Global Women’s Health Index – First Study Representing the Health of 2.5 Billion Women and Girls21.9.2021 14:00:00 EEST | Press release

Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, today shared the findings from its inaugural Hologic Global Women’s Health Index, the world’s most comprehensive, globally comparative survey about women’s health. Developed in partnership with leading analytics and advice firm Gallup, the Hologic Global Women’s Health Index is an unprecedented, in-depth examination of critical markers for women’s health, by country and territory, and over time. Its findings are based on the experiences of more than 60,000 women and girls from 116 countries and territories, captured in more than 140 languages. Conducted as part of the Gallup World Poll, which began in 2005, the Hologic Global Women’s Health Index represents the feelings and actions of approximately 2.5 billion women and girls. Based on responses from the 120,000 total individuals surveyed, women’s health needs are not being met globally. The global score was 54 out of 100 on the Index, and no one country or territory scor

CBRE GLOBAL INVESTORS JULKAISEE EUROPEAN RESIDENTIAL IMPACT FUNDIN NELJÄN SIJOITTAJAN TEKEMÄLLÄ 465 MILJOONAN EURON PÄÄOMASITOUMUKSELLA21.9.2021 13:52:00 EEST | Tiedote

Tämä on markkinointiviesti. Tutustu CBRE European Residential Impact Fund S.C.A. SICAV-SIFin perustamiskirjaan ennen lopullisten sijoituspäätösten tekemistä. Tämän julkaisun kautta ei tehdä tarjousta yhdysvaltalaisille sijoittajille. Tämä julkaisu ei muodosta tarjousta myydä tai ostaa CBRE European Residential Impact Fund S.C.A. SICAV-SIFin osakkeita tai mitään muuta tuotetta, eivätkä yhdysvaltalaiset sijoittajat voi käyttää sitä tai tukeutua siihen tehdessään sijoituspäätöksiä. Kaikki tarjoukset tehdään vain luottamuksellisen perustamiskirjan ja siihen liittyvän tilaussopimuksen kautta, jotka toimitetaan vain päteville sijoittajille. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20210921005579/fi/ Paul Oremus, CBRE European Residential Impact Fundin rahastonhoitaja (Photo: Business Wire) CBRE Global Investors, joka on yksi maailman johtavia kiinteän omaisuuden hoitoyhtiöitä, ilmoittaa tänään CBRE European Residential Impa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom